

Chemical Biological Medical Systems-Diagnostics

INVESTMENT COMPONENT

Modernization

Recapitalization

Maintenance



MISSION

Delivers safe, effective, and robust medical products that protect U.S. forces against validated CBRN threats. CBMS applies government and industry best practices to develop or acquire Food and Drug Administration (FDA)-approved products within rigorously managed cost, schedule, and performance constraints.

DESCRIPTION

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) is a reusable, portable, modifiable biological agent identification and diagnostic system capable of rapid, reliable, and simultaneous identification of multiple biological agents and other pathogens of operational concern. The ruggedized and hardened system is configured to support deployed medical personnel with the ability to identify specific biological organisms from clinical and environmental sources and samples. The JBAIDS anthrax, tularemia, plague, H5N1, and Q-fever detection systems are FDA-cleared for diagnostic use. JBAIDS is operated throughout the combat zone by medical laboratory personnel.

SYSTEM INTERDEPENDENCIES

None

PROGRAM STATUS

- **1QFY10:** FDA clearance for Avian Flu (H5N1) in vitro diagnostic (IVD) kit
- **3QFY11:** FDA clearance for Q-Fever IVD Kit
- **4QFY11:** Complete Navy fielding (31 systems)

PROJECTED ACTIVITIES

- **FY12-14:** Procurement of Next Generation Diagnostic System (NGDS)

ACQUISITION PHASE

Technology Development

Engineering and Manufacturing Development

Production and Deployment

Operations and Support

**Chemical Biological Medical
Systems-Diagnostics****FOREIGN MILITARY SALES**

None

CONTRACTORS

Idaho Technologies (Salt Lake City, UT)

